Skip to main content
Premium Trial:

Request an Annual Quote

SeqWright Makes Second Investment in VisiGen; ABI Expected to Start Alliance Before End of Year

NEW YORK, Nov. 2 (GenomeWeb News) - SeqWright has made a much-anticipated and undisclosed follow-on investment in Visigen Biotechnologies, meeting a key condition that would have kept Applied Biosystems from making its own investment in the next-generation sequencing company, SeqWright and VisiGen said today.


As GenomeWeb News reported a year ago, SeqWright paid an undisclosed amount of cash for VisiGen stock to become a shareholder. The new investment helps clear the way for ABI to invest in and collaborate with VisiGen. The companies expect that VisiGen's collaboration with ABI will begin by the end of the calendar year.


VisiGen, based in Houston, is developing a real-time sequencing system to reduce the cost of DNA sequencing.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.